Kornimate/medical-research-clean huggingface dataset:
treatment in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease has become a serious global health care and public health problems due to its high prevalence, high morbidity and heavy economic burden. acute exacerbation of chronic obstructive pulmonary disease is one of the most important causes of death in patients with copd. systemic corticosteroids therapy is recommended in copd exacerbations. in clinical practice for the treatment of acute exacerbation of copd， antibiotic application is still controversial. evidence from current guideline is based on strict criteria from randomized controlled trials, thus the given condition is simplified. patients meet the criteria account for the minority in the real world. therefore, it is still not clear whether most patients benefit from the recommended treatment. in our design, hospitalized patients with acute exacerbation of copd will be enrolled, with their treatment, arterial hypoxemia, recovery time and length of hospitalization being observed. the main purpose is to evaluate the benefit effect of current recommended treatment of acute exacerbation of copd in the real world.

chronic obstructive pulmonary disease has become a serious global health care and public health problems due to its high prevalence, high morbidity and heavy economic burden. acute exacerbation of copd is one of the most important causes of death in patients with copd. the global strategy for the diagnosis, management, and prevention of copd recommends systemic corticosteroids therapy in copd exacerbations as it can shorten recovery time, reduce treatment failure, improve lung function and arterial hypoxemia. in clinical practice for the treatment of acute exacerbation of copd， antibiotic application is still controversial. evidence from current guideline is based on strict criteria from randomized controlled trials, thus the given condition is simplified. patients meet the criteria account for the minority in the real world. therefore, it is still not clear whether most patients benefit from the recommended treatment. in our design, hospitalized patients with acute exacerbation of copd will be enrolled, with their treatment, arterial hypoxemia, recovery time and length of hospitalization being observed. the main purpose is to evaluate the benefit effect of current recommended treatment of acute exacerbation of copd in the real world.

Eligibility criteria:
inclusion criteria: * hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease * age≥ 40years old exclusion criteria: * the first diagnosis which caused hospitalization is not acute exacerbation of chronic obstructive pulmonary disease * chest radiography shows congestive heart failure * chest ct shows lung cancer, active pulmonary tuberculosis, pulmonary thromboembolism or interstitial lung diseases * serious cardiac failure, renal insufficiency or hepatic dysfunction

Keywords: acute exacerbation chronic obstructive pulmonary disease
evaluating the effect of an evidence-based one page with supplemental visual aids on the knowledge and perceptions of blood pressure management among adults with hypertension

Conditions: Hypertension

Summary: the purpose of this study is to evaluate changes in patient knowledge of blood pressure management and perceptions of making lifestyle changes to manage their blood pressure after implementation of an evidence-based one-page teaching protocol with supplemental handouts and optional use of suggested apps and web sites.


Eligibility criteria:
inclusion criteria: * adults from 18 to 75 years old * ability to self-consent * english-speaking * able to read/write english * currently prescribed at least one medication for treatment of essential primary hypertension exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners
study of genotype and phenotype expression in congenital nephrogenic diabetes insipidus

Conditions: Diabetes Insipidus, Nephrogenic

Summary: objectives: i. determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.

protocol outline: a detailed family history is obtained from all participants. whenever possible, standard growth curves of affected children are obtained. participants then undergo clinical studies of antidiuretic function. a standard fluid deprivation-vasopressin challenge is performed with timed measurements of osmolality, electrolytes, creatinine, and vasopressin. the next day, blood pressure, plasma cyclic amp, gmp, von willebrand factor, factor viii, and urine osmolality are measured during a water load desamino-d-arginine vasopressin (ddavp) infusion test. participants with a confirmed diagnosis of congenital diabetes insipidus are then treated with chlorothiazide. daily urine volume and osmolality are determined before and after therapy. sodium and fluid are not restricted. for each family, the entire vasopressin v2 gene of at least 1 affected male, and where possible at least 1 obligate carrier and 1 unaffected brother of a patient is sequenced. in addition, a detailed xq28 haplotype analysis is done to identify the origin of de novo mutations. if no mutation is found and the disorder is not transmitted in an x-linked mode, both alleles of the gene that codes for aquaporin-ii are also sequenced. dna is collected by mail from as many kindred as possible who do not participate in the clinical studies.

Eligibility criteria:
protocol entry criteria: * known or suspected congenital nephrogenic diabetes insipidus * clinically and genetically unaffected relatives entered as controls --patient characteristics-- * age: 6 months to 70 years

Keywords: diabetes insipidus endocrine disorders rare disease
retrospective survey of bone fracture in patients with arimidex 1mg

Conditions: Breast Cancer

Summary: the retrospective survey is to investigate the incidence of bone fracture in post-menopausal breast cancer patients with arimidex 1mg, who were previously registered for the clinical experience investigation.


Eligibility criteria:
inclusion criteria: * post-menopausal breast cancer patients treated with arimidex 1mg at the time of previously conducted clinical experience investigation. exclusion criteria: -

Keywords: breast cancer post-menopausal women arimidex bone fracture
hepatocellular carcinoma registry in asia: the insight registry

Conditions: Hepatocellular Carcinoma

Summary: the insight ('insight into real-world practice of management of hcc in asia-pacific') registry is designed as a multi-centre longitudinal cohort study of patients diagnosed with hcc between 1st january 2013 and 31st december 2019 in nine countries (i.e., south korea, taiwan, thailand, japan, china, hong kong, australia, new zealand and singapore). approximately 30% of the sample size will be identified retrospectively and 70% will be identified prospectively from the start date of the registry (october 2016), with an even distribution of consecutively diagnosed patients within the different years.


Eligibility criteria:
inclusion criteria: * female or male aged 21 or above. * patient with confirmed diagnosis of hcc between 1st january 2013 and 31st december 2019 based on one or more of the following criteria: * american association for the study of liver diseases (aasld) criteria * asian pacific association for the study of the liver (apasl) criteria * histology/cytology * space occupying lesion in the liver and an serum alpha-feto protein of \> 400 ng/ml in a patient with chronic viral hepatitis or cirrhosis from any cause * informed consent form (icf) to be presented and signed by patients who are still alive at the point of study enrolment, per local regulations. for the collection of data for deceased subjects, appropriate waiver of consent as per local regulations and guidelines will have to be in place. * patient who is being followed-up at the participating site. exclusion criteria: - patients participating in any hcc-related therapeutic/interventional clinical trial.
rosuvastatin in the long-term treatment of hypercholesterolaemic subjects with coronary heart disease

Conditions: Hypercholesteremia

Summary: the primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography (ivus) imaging in hypercholesterolaemic subjects with coronary heart disease (chd).


Eligibility criteria:
inclusion criteria: * signed written informed consent, * 20 to 75 years old, * plan to undergo coronary angiography (cag) or percutaneous coronary intervention (pci) and ldl-c ≥ 140 mg/dl (untreated patients) or ldl-c ≥ 100 mg/dl (treated patients) exclusion criteria: * acute myocardial infarction within 72 hours after the onset, * heart failure of new york heart association (nyha) class iii or above, * serious arrhythmia, * being treated with ldl-apheresis * history of serious reaction or hypersensitivity to other hmg-coa reductase inhibitors.
the effect of non-invasive respiratory support on outcome and its risks in severe acute respiratory syndrome coronavirus 2 (sars-cov-2)-related hypoxemic respiratory failure

Conditions: COVID-19; Hypoxemic Respiratory Failure

Summary: coronavirus disease (covid-19) can result in severe hypoxemic respiratory failure that ultimately may require invasive mechanical ventilation in the intensive care unit (icu). although lifesaving, invasive mechanical ventilation is associated with high mortality, severe discomfort for patient, long-term sequelae, stress to loved-ones and high costs for society. during the ongoing pandemic high number of invasively ventilated covid-19 patients overwhelmed icu capacity. non-invasive respiratory support, such as high flow nasal oxygen (hfno) or non-invasive ventilation (niv) have the potential to reduce the risk for invasive mechanical ventilation and in selected cases icu admission. however, data from different studies are conflicting and studies performed in covid-19 patients are of limited quality. furthermore, identification of early predictors of hfno/niv treatment failure may prevent unnecessary delay of initiation of invasive ventilation, which may be associated with adverse clinical outcome. the development and validation of a prediction model, that incorporates readily available clinically data may prove pivotal to fine-tune non-invasive respiratory support. the overall aim of the normo2 project is to investigate the role and risks of hfno and niv to improve outcome in hospitalized hypoxemic covid-19 patients.


Eligibility criteria:
inclusion criteria: * sars-cov-2 infection * hospital admission (emergency department, inpatient or icu) * hypoxemic respiratory failure, defined as p/f ratio below or including 200 exclusion criteria: * hypercapnia (pco2 \> 45 mmhg in combination with acidemia (ph \< 7.35)) * pregnancy * do not resuscitate order
mannitol bronchoprovocation challenge ancillary study/acrn

Conditions: Asthma

Summary: this is an ancillary study conducted as part of the basalt trial \[nct00495157\]. the overall hypotheses are: 1) an indirect airway challenge procedure using mannitol can safely characterize asthma phenotypes, predict asthma control and exacerbations, predict responses to interventions, and perform more specifically than a direct methacholine challenge and; 2) px27 pore function in whole blood correlates with measures of airway hyperresponsiveness induced by methacholine and/or mannitol challenges


Eligibility criteria:
inclusion criteria: * all subjects randomized to the basalt protocol exclusion criteria: * positive urine pregnancy test * requirement for more than two albuterol treatments for reversal of the methacholine bronchoprovocation challenge procedure at visit 4 in the basalt parent trial

Keywords: asthma bronchoprovocation challenge test mannitol methacholine
the therapy of nebido as mono or in combination with pde-5 inhibitors in hypogonadal patients with erectile dysfunction

Conditions: Hypogonadism; Erectile Dysfunction

Summary: the purpose of this study is to evaluate the response of a treatment with testosterone undecanoate and determine the levels of total and free testosterone in hypogonadal patients with erectile dysfunction.

hypogonadism is a pathophysiologic and clinical factor in a substantial number of patients with ed,and data indicate that a threshold level of testosterone is necessary for normal erectile function.testosterone therapy is clearly indicated in hypogonadal patients and is beneficial in other patients with ed and hypogonadism.however,testosterone efficacy as monotherapy for ed could be limited,and combination therapy with testosterone and other ed treatments,such as pde-5 inhibitors may be valuable in certain subpopulations of patients.

Eligibility criteria:
inclusion criteria: 1. patients with ed over 3 months (specify using iief score) 2. age \>= 18 years. 3. stable sexual relationship 4. with low or low normal serum testosterone level (either total or bioavailable testosterone) tt \<= 4 ng/ml and/or bt \<= 1 ng/ml 5. aging male symptom scale with total score starting at 37 points (must not replace tt \< 4 ng/ml) 6. eligible subjects who previously took the oral androgen or pde5 inhibitor must have discontinued their use for 1 month exclusion criteria: 1. contraindication to treatment with testosterone according to the spc 2. hypersensitivity to the active substances or any of the excipients of nebido 3. diagnosed or suspected carcinoma of the prostate or the male breast cancer 4. past or present liver tumors 5. acute or chronic hepatic diseases 6. severe cardiac, hepatic or renal insufficiency 7. history of penile implant or significant penile deformity 8. diagnosed sleep apnea 9. polycythemia (hematocrit \>50%) 10. prolactin \>25 ng/ml 11. organic hypothalamic-pituitary pathology 12. any unstable medical, psychiatric or drug/alcohol abuse disorder 13. prostate specific antigen (psa)\>= 4 ng/ml 14. severe symptomatic benign prostatic hyperplasia (ipss) sum score \>=20) 15. diabetes mellitus which is uncontrolled (hbalc level \>10%) 16. epilepsy not adequately controlled by treatment 17. patients requiring fertility treatment 18. hypertension which is not adequately controlled on therapy 19. clinically significant chronic hematological disease which may lead to priapism such as sickle cell anemia, multiple myeloma or leukemia 20. hypersensitivity to pde-5 inhibitors 21. concomitant medication: * nitrites or nitric oxide donors * anti-androgens * anti-coagulants, with the exception of anti-platelet agents * any of potent inhibitors of cytochrome p-450 3a4:such as hiv protease inhibitors (ritonavir or indinavir); anti-mycotic agent (itraconazole and ketoconazole)-topical application allowed; or erythromycin.

Keywords: nebido in hypogonadism with erectile dysfunction
clinical outcomes of high dose vitamin d versus standard dose in covid-19 egyptian patients

Conditions: Covid19; Corona Virus Infection; Cytokine Storm; Vitamin D Deficiency

Summary: vitamin d is a secosteroid hormone which may have beneficial role in reducing covid-19 adverse outcomes by first regulating the renin angiotensin system (ras). recent studies on animal in which acute respiratory distress syndrome (ards) was induced, showed that vitamin d lead to pulmonary permeability reduction by modulating ras activity as well as the expression of the angiotensin-2 converting enzyme (ace2). during covid-19, downregulation of ace2 leads to cytokine storm in the host, causing ards. in contrast, an experimental study conducted on mice in which ards was induced chemically, revealed that vitamin d admiration contributed to mrna and ace2 proteins levels improvement, adrs milder symptoms as well as less lung damage. additionally, vitamin d had shown antiviral effects on several previous studies, that though to be exerted either by antimicrobial peptides induction which subsequently had direct antiviral action or through immunomodulatory and anti-inflammatory effects. in addition, vitamin d stabilizes physical barriers which prevent viruses from reaching tissues susceptible to infection. finally, previous studies demonstrated that hypovitaminosis d is accompanied by various comorbidities including diabetes mellitus, hypertension, chronic cardiovascular and respiratory diseases, and cancers, all medical conditions that are considered risk factors of covid-19 infection deterioration and even high mortality rate. the objective of this study is to evaluate whether supplementation with high-dose vitamin d improves the prognosis of patients diagnosed with covid-19 compared to a standard dose of vitamin d.


Eligibility criteria:
inclusion criteria: 1. age 18 to 65 years. 2. covid-19 hospitalized patients with pneumonia confirmed by chest x-ray or ct scan. 3. rt-pcr confirmed infection with covid-19 or strongly suspected infection with pending confirmation studies. 4. presence of acute respiratory distress syndrome (ards). 5. having either peripheral capillary oxygen saturation (spo2) ≤ 94% ambient air, or a partial oxygen pressure (pao2) to fraction of inspired oxygen (fio2) ratio ≤ 300 mmhg. exclusion criteria: 1. vitamin d supplementation in the previous month. 2. contraindication for vitamin d supplementation: active granulomatosis (sarcoidosis, tuberculosis, lymphoma), history of calcic lithiasis, known hypervitaminosis d or hypercalcemia, known intolerance to vitamin d. 3. organ failure requiring admission to a resuscitation or high dependency unit. 4. pregnant women. 5. participation in another simultaneous clinical trial.

Keywords: covid-19 cytokine storm vitamin d
korean brain aging study for early diagnosis and prediction of alzheimer's disease

Conditions: Alzheimer's Disease; Mild Cognitive Impairment

Summary: this is a prospective cohort study for cognitively normal (young and old), mild cognitive impairment, and alzheimer's disease people

the aim of the study is 1) to search new biomarkers and develop clinically applicable early diagnosis and prediction methods of alzheimer's disease, and 2) to investigate how the proposed lifetime risk and protective factors for alzheimer's disease contribute to pathological hallmarks of ad or other brain changes in living human through annual comprehensive clinical and neuropsychological evaluation and biannual brain imaging (mri and mra, fluorodeoxyglucose(fdg)-pet, pittsburgh compound b (pib)-pet), av--1451 pet, and body specimen (blood, gene, and hair) analysis. \* note: av-1451 pet will not be applied to whole subjects, but to 210 subjects (30 young cn, 60 old cn, 60 mci, and 60 ad).

Eligibility criteria:
participants will be classified as either alzheimer's disease(ad) group, mild cognitive impairment(mci) group, elderly normal controls or young normal controls. specific inclusion criteria for each group is described below. \[inclusion criteria: ad\] * age : 55 - 90 * clinical dementia rating (cdr)=0.5 or 1 * diagnostic and statistical manual-iv(dsm-iv) criteria for dementia * national institute of aging and the alzheimer's association (nia-aa) probable ad dementia * study partner or caregiver to accompany patient to all scheduled visits * written informed consent \[inclusion criteria: mci (amnestic)\] * age : 55 - 90 * clinical dementia rating (cdr)=0.5 * concern regarding a change in cognition (obtained from the subject, from an informant who knows the subject, or from a skilled clinician observing the subject) * lower performance in episodic memory domains that is greater than would be expected for the subject's age and educational background * preservation of independence in functional abilities * study partner or caregiver to accompany subject to all scheduled visits * written informed consent \[inclusion criteria: elderly normal controls\] * age : 55 - 90 * clinical dementia rating (cdr)=0 * those with contactable informant * written informed consent \[inclusion criteria: young normal controls\] * age : 20 - 55 * clinical dementia rating (cdr)=0 * written informed consent \[exclusion criteria: general\] * past history or presence of major psychiatric illness (e.g. schizophrenia, bipolar disorder, alcohol/substance abuse or dependence, delirium) * significant neurologic or medical condition that can influence the mental state * contraindications for mri scan (e.g. pacemaker, claustrophobia) * illiteracy * significant visual or hearing difficulty * taking investigational drug * in pregnancy or breast-feeding

Keywords: alzheimer's disease early diagnosis prediction biomarker imaging
the radiance ii pivotal study: a study of the recor medical paradise system in stage ii hypertension

Conditions: Hypertension; Vascular Diseases; Cardiovascular Diseases

Summary: the objective of the radiance ii pivotal study is to demonstrate the effectiveness and safety of the paradise system in subjects with stage 2 hypertension on 0-2 medications at the time of consent. prior to randomization, subjects will be hypertensive in the absence of hypertension medication.


Eligibility criteria:
inclusion criteria: * previously or currently prescribed antihypertensive therapy * average office bp ≥ 140/90 mmhg \<180/120 mmhg while stable for at least 4 weeks on 0-2 classes of antihypertensive medication * documented daytime abp ≥ 135/85 mmhg and \< 170/105 mmhg after 4-week washout/run-in period exclusion criteria: * lacks appropriate renal artery anatomy for treatment * known, uncorrected causes of secondary hypertension other than sleep apnea * type i diabetes mellitus or uncontrolled type ii diabetes * egfr of \<40 * brachial circumference ≥ 42 cm * any history of cerebrovascular event or severe cardiovascular event, or history of stable or unstable angina within 12 months prior to consent * repeat (\>1) hospitalization for hypertensive crisis within 12 months prior to screening period, or any hospitalization for hypertensive crisis within 3 months prior to screening period * chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea * primary pulmonary hypertension * night shift workers * pregnant, nursing or planning to become pregnant

Keywords: denervation resistant hypertension essential hypertension uncontrolled hypertension